Key Highlights

● First-half revenue rose to US$44.5 million from US$32.6 million a year earlier.

● The net loss widened to US$120.4 million from US$82.5 million.

● Cash and bank balances were US$279.4 million, down from US$353.2 million at year-end.

● Olverembatinib and lisaftoclax are both approved in China, with Phase III studies under way.

The Nasdaq-listed security is the American depositary share (ADS) of Ascentage Pharma Group International (NASDAQ:AAPG), trading as AAPG. Each ADS represents four ordinary shares, according to the company's January 2025 announcement of its US initial public offering, in which 7,325,000 ADSs were priced at US$17.25 each for gross proceeds of about US$126.4 million. The ordinary shares are also listed on the Hong Kong Stock Exchange under code 6855. The company's interim release says the "B" marker has since been removed from its Hong Kong short name. Ascentage develops targeted therapies for haematological cancers and sells products in China.

First-half 2026 financial results

On 19 August 2026 Ascentage reported unaudited results for the six months ended 30 June 2026. Revenue was US$44.5 million (RMB302.2 million), compared with US$32.6 million (RMB233.7 million) in the first half of 2025, an increase of 29.3% on a constant-currency basis. Product sales accounted for US$41.6 million. The company translated figures at RMB6.7851 per US dollar for the period.

Spending rose faster than revenue. Research and development expenses were US$102.8 million, up from US$73.8 million, driven by global clinical trials. Selling and distribution expenses reached US$33.4 million from US$19.2 million, mainly reflecting marketing of lisaftoclax, and administrative expenses were US$17.5 million. The net loss widened to US$120.4 million (RMB817.0 million) from US$82.5 million, or US$0.32 per share against US$0.24. Cash and bank balances were US$279.4 million at 30 June 2026, down from US$353.2 million at 31 December 2025, and 373,555,768 ordinary shares were outstanding.

Commercial products and pipeline

Olverembatinib is described as the first third-generation BCR-ABL1 tyrosine kinase inhibitor approved in China, for chronic myeloid leukaemia patients with T315I mutations and for chronic-phase patients resistant or intolerant to earlier-generation treatments. It is covered by China's National Reimbursement Drug List (NRDL), and its availability widened to 879 pharmacies and hospitals at 30 June 2026 from 782. The company has registrational Phase III studies under way: POLARIS-1 in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia, POLARIS-2 in previously treated chronic-phase disease, and POLARIS-3 in succinate dehydrogenase-deficient gastrointestinal stromal tumours.

Lisaftoclax, a Bcl-2 inhibitor, is approved by China's regulator for adult chronic lymphocytic leukaemia or small lymphocytic lymphoma patients who have previously received a BTK inhibitor, and was available at 415 pharmacies and hospitals. Phase III studies named in the release are GLORA, GLORA-2, GLORA-3 and GLORA-4, covering leukaemia and myelodysplastic syndrome settings. The company said it plans to seek NRDL inclusion for lisaftoclax in China in 2026. Separately, APG-3288, a BTK degrader, received US FDA investigational new drug clearance in January 2026 and China clearance in February 2026, and a Phase I study is ongoing.

Management changes and next steps

The release also announced the appointment of Dr Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. Mandarin and English-language investor webcasts were scheduled for 20 August 2026 (Hong Kong and New York time respectively) and have therefore already taken place.

Widening Losses, a Falling Cash Balance and Phase III Milestones

The figures are the company's own unaudited results, and the release gives no guidance on revenue or loss. The loss widened as trial and commercial costs grew, and the cash balance fell by about US$73.8 million in six months, so future funding needs and the pace of Phase III enrolment are central uncertainties. Clinical results, regulatory decisions and reimbursement outcomes are unpredictable, and approval in China does not imply approval elsewhere. ADS holders are also exposed to currency movements between the renminbi, which is used for much of the company's reporting, and the US dollar.